Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly ADP Ribose Polymerase (PARP) Inhibitor”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Early research (Phase 1)Study completedNCT03343054
What this trial is testing

Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Who this might be right for
NeoplasmsBreast Neoplasms
Pfizer 28
Testing effectiveness (Phase 2)WithdrawnNCT04239014
What this trial is testing

Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Who this might be right for
Ovarian Cancer
AstraZeneca
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Early research (Phase 1)Study completedNCT01009190
What this trial is testing

Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Who this might be right for
Advanced Solid Tumors
pharmaand GmbH 85
Testing effectiveness (Phase 2)Study completedNCT05751629
What this trial is testing

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Neoplasm
Tesaro, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Not applicableUnknownNCT05310370
What this trial is testing

HRD and Resistance to PAPPi in EOC Patients

Who this might be right for
Epithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more
Lei Li 400
Testing effectiveness (Phase 2)Study completedNCT03574779
What this trial is testing

Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 77
Testing effectiveness (Phase 2)Study completedNCT04740190
What this trial is testing

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Who this might be right for
Recurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) Inhibitor+2 more
The University of Hong Kong 33
Early research (Phase 1)Study completedNCT00994071
What this trial is testing

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Who this might be right for
MedulloblastomaPontine GliomaEpendymoma+2 more
National Cancer Institute (NCI) 9
Early research (Phase 1)Study completedNCT00633269
What this trial is testing

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05286827
What this trial is testing

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Who this might be right for
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05898399
What this trial is testing

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Who this might be right for
Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd 220
Testing effectiveness (Phase 2)Study completedNCT01051596
What this trial is testing

ABT-888 in Combination With Temozolomide for Colorectal Cancer

Who this might be right for
Colorectal Cancer
Georgetown University 75
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Early research (Phase 1)WithdrawnNCT04149145
What this trial is testing

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
University of Alabama at Birmingham
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Early research (Phase 1)Ended earlyNCT01127178
What this trial is testing

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Eisai Inc. 12
Early research (Phase 1)Ended earlyNCT03944902
What this trial is testing

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Who this might be right for
Ovarian CancerResistant BRCA Wild-Type Ovarian Cancer
University of Alabama at Birmingham 1
Testing effectiveness (Phase 2)Study completedNCT00271765
What this trial is testing

INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Who this might be right for
Acute Myocardial Infarction
Inotek Pharmaceuticals Corporation 40
Load More Results